Impact of soybean bioactive compounds as response to diet-induced chronic inflammation: A systematic review

Food Res Int. 2022 Dec;162(Pt A):111928. doi: 10.1016/j.foodres.2022.111928. Epub 2022 Sep 14.

Abstract

Chronic inflammation refers to long-lasting inflammation that occurs over a period of several months to years, and it is associated with the progression of other chronic diseases. It may be induced by alcohol consumption and a high-fat diet. Soybean bioactive compounds prevent chronic inflammation by primarily targeting the nuclear factor kappa B (NF-κB) pathway, which inhibits the phosphorylation of IkappaB kinase complex (IκB) and reduces inflammatory marker levels. We performed a systematic review of studies published between 2012 and 2022 on the impact of soybeans on diet-induced chronic inflammation. Soy bioactive compounds may mitigate chronic inflammation. However, more human intervention studies are needed to assess their efficacy as potential modulating agents for inflammation and inflammation-related diseases. The objective was to review the impact of soy-derived bioactive compounds on high-fat diet-induced and alcohol-induced inflammation. To our knowledge, it is the first review to look specifically at high-fat diet-induced and alcohol-induced inflammation and how it is modulated by specific bioactive compounds in soybean.

Keywords: Bowman-Birk inhibitor; Chronic inflammation; High-fat diet; Isoflavones; Lipid; Lunasin; Peptides; Saponin; Soybean; Systematic review.

Publication types

  • Systematic Review
  • Review
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Diet, High-Fat / adverse effects
  • Ethanol
  • Fabaceae*
  • Glycine max*
  • Humans
  • Inflammation
  • NF-kappa B

Substances

  • NF-kappa B
  • Ethanol